Helen Jackson is Senior Project Leader in RIA iMed (Respiratory Inflammation & Autoimmune Innovative Medicines) leading global R&D project teams delivering novel inhaled anti-inflammatory & bronchodilator drug combinations for Asthma & COPD. Helen is also a Member of RIA iMed Leadership Team & Review Board which are responsible for the disease area strategy and ensuring that target selection and the early portfolio are aligned with this including evaluation of in-licensing opportunities and ensuring effective working for new and established development collaborations.